Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Reported total revenue of $10.3 million and GAAP Net Income of$ 0.6 million, or $0.02 per diluted shareEntered into an asset purchase agreement to acquire Increlex® (mecasermin injection)Q3 2024 product sales increased 40% over Q3 2023, representing 15th straight quarter of sequential product sales growthProduced positive quarterly GAAP net income from product sales for first time in company historyGenerated cash from operations of$ 2.9 million in Q3 2024Granted additional patent for ET-400Management to hol ...